Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III non-inferiority study of GSK 10-valent pneumococcal conjugate vaccine versus Prevenar in Korean infants
2015-001505-14Phase 3
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of 10-valent pneumococcal and non-typeable haemophilus influenzae protein d conjugate vaccine, pneumococcal 7-valent conjugate vaccine and haemophilus influenzae type b vaccine in pneumococcal disease and Haemophilus influenzae type b disease (Hib) (2 arms), sponsored by GSK.
02
Drugs
10-valent pneumococcal and non-typeable haemophilus influenzae protein d conjugate vaccinepneumococcal 7-valent conjugate vaccinehaemophilus influenzae type b vaccine
03
Conditions
pneumococcal diseaseHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2015-001505-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001505-14.